Loading…
Amylyx Pharmaceuticals, Inc. is projected to rise to $25.03 by 2027, a +41% move from its current price of $17.77. AMLX is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $17.34 | $17.79 | $18.24 | +0.09% |
| Jul 14 | $17.17 | $17.80 | $18.45 | +0.18% |
| Jul 15 | $17.05 | $17.82 | $18.62 | +0.26% |
| Jul 16 | $16.95 | $17.83 | $18.76 | +0.35% |
| Jul 17 | $16.86 | $17.85 | $18.89 | +0.44% |
| Jul 18 | $16.78 | $17.86 | $19.01 | +0.53% |
| Jul 19 | $16.72 | $17.88 | $19.12 | +0.62% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $16.72 | $17.88 | $19.12 | +0.62% |
| Week 2 | $16.36 | $17.99 | $19.79 | +1.24% |
| Week 3 | $16.11 | $18.10 | $20.34 | +1.86% |
| Week 4 | $15.92 | $18.21 | $20.84 | +2.49% |
| Week 5 | $15.76 | $18.32 | $21.30 | +3.12% |
| Week 6 | $15.64 | $18.44 | $21.74 | +3.76% |
| Week 7 | $15.53 | $18.55 | $22.17 | +4.40% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Amylyx Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company focused on discovery and development of treatments for neurodegenerative diseases and endocrine conditions in the United States. The company provides Avexitide, an investigational, first-in-class GLP-1 receptor antagonist, which is in phase 3 clinical trials to treat post-bariatric hypoglycemia and congenital hyperinsulinism.
It also develops AMX0035, an oral fixed-dose combination of sodium phenylbutyrate and taurursodiol, which is in phase 2/3 clinical trials for wolfram syndrome and in phase 2b/3 for progressive supranuclear palsy, as well as AMX0114, which is in phase 1 clinical trials for amyotrophic lateral sclerosis. Long-acting GLP-1 receptor antagonists for post-bariatric hypoglycemia and other rare diseases, and AMX0318, a GLP-1 receptor antagonist for the treatment of post-bariatric hypoglycemia and other rare diseases, are among its development programs. Amylyx was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Amylyx Pharmaceuticals, Inc. trades in the healthcare sector under the AMLX ticker. The stock currently quotes at $18.70 with a market capitalization of $2.08B and a market-rank position of 1921. The price action and forecasts place the asset on a path of potential long-term upside, tempered by near-term variability.
A major floor 39.2% below — a decisive break under it would weaken the trend.
The nearest floor, 26.8% below — buyers have tended to step in here.
The nearest ceiling, 5.2% above — a clean break opens room to run.
A major ceiling 24.8% above — clearing it would confirm fresh momentum.
Key AMLX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of AMLX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $18.03 | Sell | $18.00 | Sell |
| MA 10 | $18.08 | Sell | $17.76 | Buy |
| MA 20 | $16.88 | Buy | $17.02 | Buy |
| MA 50 | $15.33 | Buy | $15.96 | Buy |
| MA 100 | $15.25 | Buy | $15.25 | Buy |
| MA 200 | $14.48 | Buy | $13.85 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 60.40 | Neutral |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | 46.65 | Neutral |
| Williams %R (14) | -38.43 | Info |
| MACD (12,26,9) | 0.04 | Buy |
| ROC (12) | 8.55 | Buy |
| Bollinger %B (20,2) | 0.66 | Neutral |
| Stochastic %K (14) | 61.57 | Neutral |
| TRIX (15) | 0.87 | Buy |
| Awesome (5,34) | 2.46 | Buy |
| Ultimate (7,14,28) | 54.49 | Neutral |
| Momentum (10) | 0.33 | Buy |
| Aroon Osc (25) | 56.00 | Buy |
| Hull MA (9) | 18.04 | Sell |
| ADX (14) | 28.71 | Buy |
| ATR (14) | 0.42 | Info |
The 30-day technical picture is bullish with an RSI of 80. The stock sits above the 50-day simple moving average of $15.21 and above the 200-day simple moving average of $14.26. Near-term support is at $12.74 and resistance at $18.70.
The 30-day price range is from $15.55 to $22.49, indicating a near-term trading corridor with notable upside potential beyond the upper end of the range. Annualized volatility is high at 50%, underscoring substantial price swings within the month.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $11.38 | $17.77 | $25.50 | 0% | Neutral | |
| $20.06 | $25.03 | $32.97 | +41% | Bullish | |
| $28.30 | $36.24 | $49.43 | +104% | Bullish | |
| $34.24 | $44.80 | $62.79 | +152% | Bullish | |
| $36.05 | $48.06 | $68.92 | +170% | Bullish | |
| $42.32 | $57.40 | $83.99 | +223% | Bullish | |
| $46.41 | $63.95 | $95.28 | +260% | Bullish | |
| $52.83 | $73.89 | $111.91 | +316% | Bullish | |
| $69.21 | $98.18 | $150.94 | +453% | Bullish | |
| $75.44 | $108.48 | $169.11 | +510% | Bullish | |
| $125.67 | $192.09 | $317.56 | +981% | Bullish | |
| $237.45 | $402.84 | $725.64 | +21.7x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $11.38 | $17.77 | $22.05 | +0.00% |
| August 2026 | $16.32 | $19.22 | $23.23 | +8.19% |
| September 2026 | $16.24 | $19.25 | $23.51 | +0.14% |
| October 2026 | $16.59 | $19.78 | $24.36 | +2.74% |
| November 2026 | $17.13 | $20.52 | $25.46 | +3.74% |
| December 2026 | $16.96 | $20.41 | $25.50 | -0.51% |
Click any year to see its month-by-month AMLX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, AMLX could reach as high as $25.50, with a base case around $17.77 and support toward $11.38 — roughly 0% from $17.77. A consolidation phase looks the most probable path here.
Expect AMLX to range from $20.06 to $32.97 through 2027. The $25.03 average target implies a +41% move from current prices. That is up +41% on the projected 2026 average. Momentum favours further upside here.
The AMLX price prediction for 2028 points to an average of $36.24 (low $28.30, high $49.43) — a potential gain of +104% on today's $17.77. Buyers look set to stay in control over this stretch.
In 2029, AMLX is projected to trade between $34.24 and $62.79, averaging $44.80 — a potential gain of +152% from today's $17.77. That is up +24% on the projected 2028 average. Momentum favours further upside here.
Amylyx Pharmaceuticals, Inc.'s 2030 outlook centres on $48.06, within a $36.05 to $68.92 range. That is up +7% on the projected 2029 average. That marks a +170% change versus current levels. Buyers look set to stay in control over this stretch.
By 2031, AMLX could reach as high as $83.99, with a base case around $57.40 and support toward $42.32 — roughly +223% from $17.77. Momentum favours further upside here.
Expect AMLX to range from $46.41 to $95.28 through 2032. The $63.95 average target implies a +260% move from current prices. That is up +11% on the projected 2031 average. Buyers look set to stay in control over this stretch.
The AMLX price prediction for 2033 points to an average of $73.89 (low $52.83, high $111.91) — a potential gain of +316% on today's $17.77. Momentum favours further upside here.
In 2034, AMLX is projected to trade between $69.21 and $150.94, averaging $98.18 — a potential gain of +453% from today's $17.77. That is up +33% on the projected 2033 average. Buyers look set to stay in control over this stretch.
Amylyx Pharmaceuticals, Inc.'s 2035 outlook centres on $108.48, within a $75.44 to $169.11 range. That is up +10% on the projected 2034 average. That marks a +510% change versus current levels. Momentum favours further upside here.
By 2040, AMLX could reach as high as $317.56, with a base case around $192.09 and support toward $125.67 — roughly +981% from $17.77. Buyers look set to stay in control over this stretch.
Expect AMLX to range from $237.45 to $725.64 through 2050. The $402.84 average target implies a +21.7x move from current prices. That is up +110% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in AMLX today (≈ 56.27462 AMLX) could be worth
$22,669.72
+$21,669.72 (+2167%) by 2050 · US Dollar
Based on the average projected AMLX price of $402.84 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in AMLXwould be worth at today's price.
$1,000 invested in AMLX on Jul 10, 2025 (≈ 135.318 AMLX) would be worth
$2,404.6
+$1,404.6 (+140.5%) today · 2.40× · US Dollar
Based on a AMLX entry price of $7.39 vs. today's $17.77.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $18.27 | $972.63 | -2.7% |
| 1 month ago | $13.46 | $1,320.21 | +32.0% |
| 3 months ago | $16.36 | $1,086.19 | +8.6% |
| 6 months ago | $12.39 | $1,434.22 | +43.4% |
| 1 year ago | $7.39 | $2,404.6 | +140.5% |
| All time (4.5y) ago | $18.07 | $983.4 | -1.7% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our AMLX forecast.
Our base-case forecast reaches $36.00 around 2028.
Implied market cap at $36.00: $4B
The multi-year forecast shows a sustained upward trajectory, with 2026 forecasts centering around $18.70 (min $11.38, max $26.98; ROI 0; sentiment NEUTRAL). From 2027 onward, the averages rise notably: 2027 avg $27.32 (min $21.68, max $36.47; ROI 46.1; sentiment BULLISH), 2028 avg $39.38 (min $30.38, max $54.57; ROI 110.6), 2029 avg $47.62 (min $35.87, max $67.95; ROI 154.6), 2030 avg $51.20 (min $37.77, max $74.88; ROI 173.8). The forecast continues to climb through 2035, with 2031 avg $60.93 (ROI 225.8), 2032 avg $67.22 (ROI 259.5), 2033 avg $79.43 (ROI 324.7), 2034 avg $105.95 (ROI 466.6), and 2035 avg $114.88 (ROI 514.3).
By 2040, the average is projected at $208.52 (min $131.89, max $355.07; ROI 1015.1), and by 2050 at $416.80 (min $233.97, max $777.54; ROI 2128.9), with sentiment remaining BULLISH across the horizon.
Tap a question to reveal the answer.
The year 2030 forecast shows an average price of $51.20 with a range from $37.77 to $74.88 and a forecasted ROI of 173.8, with sentiment rated BULLISH.
The forecast shows bullish sentiment beginning in 2027 with increasing average prices through 2030 and beyond (2031–2050), and escalating ROIs such as 46.1 in 2027, 110.6 in 2028, 154.6 in 2029, 173.8 in 2030, 1015.1 in 2040, and 2128.9 in 2050, after a neutral stance in 2026.
Yes. The forecast maximums exceed $100 in several years, including $102.42 in 2032 and $123.15 in 2033, with higher maxima in later years (e.g., $355.07 in 2040 and $777.54 in 2050).
The current price is $18.70. The 30-day range is from $15.55 to $22.49, with near-term support at $12.74 and resistance at $18.70.
By 2050, the average forecast price is $416.80 with a maximum of $777.54 and a minimum of $233.97, corresponding to an ROI of 2128.9 and a bullish sentiment. The pathway includes substantial upside from 2027 onward, culminating in a very high long-term valuation if the forecast unfolds.
Amylyx Pharmaceuticals, Inc. Community Discussion
0Share your Amylyx Pharmaceuticals, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.